CD274 and hepatocellular carcinoma: Durvalumab, an anti-PD-L1 mAb, alone or combined with bevacizumab, is under examination in a phase III, randomized, double-blind, placebo-controlled, multicenter study, EMERALD-2 (NCT03847428), in the same HCC high-risk population of the abovementioned studies.